Having trouble reading this email? View in your browser

 
 

News on the first potential progressive MS treatment, 200 researchers gather to drive progressive MS science forwards, and new reports on all of the grants you've funded so far.

Plus we are delighted to welcome MS Hope for a Cure (USA), who recently joined the International Progressive MS Alliance as our first Foundation Member.

FDA grants 'priority review' for progressive MS treatment

There are currently no approved disease-modifying therapies to treat progressive MS, but a recent announcement from Genentech, a member of the Roche group, announced that the U.S. Food and Drug Administration (FDA) granted the OCREVUS™ (ocrelizumab) application Priority Review Designation.
 
With a decision to be taken as early as December 2016 this could be the first treatment on the market for any form of progressive MS.
 

 

Report from the second Alliance Scientific Congress

Research on progressive MS is advancing, with the first modest treatment success recently reported and more paths opening for understanding what’s driving the disease, but with many challenges remaining.

That was the take-home message from the International Progressive MS Alliance’s Second Scientific Congress, where more than 200 researchers and supporters gathered in San Francisco in May 2016 to review research progress, challenges and next steps to speed the development of therapies for progressive MS.

 

Update on Challenge and Infrastructure awards

In 2014, the International Progressive MS Alliance awarded their first Challenge Awards to encourage scientific innovation, and Infrastructure Awards to promote data sharing and knowledge management.

A total of 22  projects, with researchers based in nine countries, were awarded with total funding of just over €1.6 million. The projects focused on clinical trials and outcome measures, biomarkers (measureable indicators) of progression, gene studies, rehabilitation trials, new disease models, and research to better understand the pathology of progression.

We now have updates on these projects.

 

 

This email was sent on behalf of the Progressive MS Alliance by: MS International Federation
Skyline House, 200 Union Street, London SE1 0LX United Kingdom

MS International Federation is a charity and company limited by guarantee, registered in England and Wales. Company No: 05088553. Registered Charity No: 1105321

We respect your privacy, please read our policy.

You are receiving this email because you have signed up to receive updates on our work. If you no longer wish to receive these, please unsubscribe or manage your subscription preferences.

MS International Federation would like to thank Genzyme and EMD Serono for their kind support for this newsletter. MS International Federation has full editorial control of all its communications.